Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to inform healthcare interventions to reduce the disparities in liver transplant listing and in transplantation.
Aim 1. Establish a longitudinal cohort of patients with end-stage liver dysfunction.
Aim 2. Examine interpersonal and structural factors associated with liver transplant evaluation and listing by patient characteristics (e.g., race, ethnicity, SES, gender).
Aim 3. Examine the use of stigmatizing language among patients undergoing liver transplant based on their demographic characteristics (e.g., race, ethnicity, SES, gender).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Liver Transplant Patients | Subjects with end-stage liver disease and being referred for transplant evaluation will fill out questionnaires about their background, emotions, and behaviors. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Liver transplant waiting list | Number of subjects listed on the liver transplant waiting list | Approximately one year |
| Organ transplantation | Number of subject to receive an organ transplantation | Approximately one year |
| Measure | Description | Time Frame |
|---|---|---|
| Survival | Total number of subject alive | Approximately one year post-transplant, or until you are removed from the transplant list |
| Graft survival at six months | Total number of subject to have a functioning graft at six months post transplant |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | Total number of subject deaths | Approximately one year post-transplant, or until you are removed from the transplant list |
| Hospital length of stay | Total number of days subjects were admitted to the hospital |
Inclusion Criteria:
- Patients with end-stage liver, kidney, or cardiac dysfunction.
Exclusion Criteria:
Not provided
Not provided
Not provided
Subjects identified with end-stage liver receiving initial stage of transplant evaluation at Mayo Clinic Arizona.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gabrielle Montefiore | Contact | 480-574-1288 |
| Name | Affiliation | Role |
|---|---|---|
| Peter E. Frasco, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic Arizona | Recruiting | Phoenix | Arizona | 85054 | United States |
Not provided
| Label | URL |
|---|---|
| Mayo Clinic Clinical Trials | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D058625 | End Stage Liver Disease |
| D003142 | Communication |
| ID | Term |
|---|---|
| D017093 | Liver Failure |
| D048550 | Hepatic Insufficiency |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Six months post transplant |
| Graft survival at one year | Total number of subject to have a functioning graft at one year post transplant | One year post transplant |
| Approximately one year post-transplant, or until you are removed from the transplant list |
| ICU length of stay | Total number of days subjects were admitted to Intensive Care Unit (ICU) | Approximately one year post-transplant, or until you are removed from the transplant list |
| 30-day readmission | Number of subjects to experience a 30-day readmission | Approximately one year post-transplant, or until you are removed from the transplant list |
| D001519 |
| Behavior |